The Phase II study has achieved positive results for the application of the investigational drug tagraxofusp in tackling a rare but often fatal bone marrow and blood disorder.
Patients with anxiety, depression or OCD tend to place more emphasis on potential negative consequences than positive ones when faced with difficult decisions, often leading to irrational decisions or even inability to react.
Glaucoma, diabetic retinopathy and age-related macular degeneration are among the diseases that threaten visual acuity.
Can chemotherapy cause the onset of metastases or accelerate their formation?
Can an advanced age be the reason for withholding targeted therapies from patients with Rheumatoid Arthritis (RA)?
To find out more about this new innovation in telemedicine, we went to meet the team at ADA, an application that helps patients and physicians to reach and provide a more accurate diagnosis.
People aged 75 and over account for about one-third of heart attack patients, and more than half of them die in the hospital as a result of the infarction. So far it was not known whether the mental condition influences the prognosis of older heart attack patients.
Anticoagulation is the therapy of choice after pulmonary embolism (PE). Whereas in the past heparin and other vitamin K antagonists (VKA) were mainly used, NOACs are now the most common. Uncertainty often prevails in tumor patients, who naturally carry a higher risk of thrombosis.
NOACs are recommended by the ESC guideline as the primary choice for patients with oral anticoagulation. Compared to the previous standard warfarin, they offer great advantages in stroke prevention, as randomized clinical trials (RCT) have shown. But what about the real world in practice? What do the data say and how valid are they?
Almost every day, patients and their physicians are confronted with new wisdom about nutrition and its resulting consequences. So far, however, the advice for healthy eating has always been quite unanimous in the same direction. But the PURE study questions some of the previous dogmas of nutritional science and thus very probably creates greater uncertainty.
Patients with atrial fibrillation receive anticoagulation therapy as standard. This is supplemented by dual platelet inhibition in the presence of acute coronary syndrome (ACS). The main concern of doctor and patient is the risk of severe bleeding events. What combinations of drugs are possible here? Is acetylsalicylic acid (ASA) an option in combined anticoagulation therapy for these patients?
The new US guideline already defines a blood pressure of 130/80 mm Hg measured during the day as hypertension. Literally, overnight, every second US American suddenly became a high-pressure patient. Does hypertension now also have to be redefined in Europe?
Atrial fibrillation (A-fib) is still discovered in many patients by chance or only after a stroke. Experts at the ESC 2018, therefore, urged once again that risk patients be screened more regularly for A-fib. After all, diagnosis is an important starting point for reducing the risk of stroke.
The results of the ASCEND study published at the ESC Congress 2018 and in the New England Journal of Medicine show what many have always suspected: Fish oil preparations have absolutely no effect on patients with diabetes. According to Professor Louise Bowman, there is no justification for recommending fish oil preparations to protect against cardiovascular events. A reconsideration of the European Guidelines in this respect should, therefore, be considered.
Atrial fibrillation (A-fib) is one of the main risk factors for stroke. For a long time, vitamin K antagonists (VKA) such as warfarin were the drugs of choice in anticoagulation therapy for A-fib. Today, however, the ESC guideline recommends new oral anticoagulants (NOAC) for patients with A-fib in the majority of cases.
In the year 2018, the ESC again asked - even more than ever - the question of the right method for measuring blood pressure. Meanwhile, there are many different electronic, automatic and semi-automatic blood pressure monitors in addition to the classic type.
Whether aspirin should be used to prevent a cardiovascular event remains uncertain. According to the latest studies, the advantages of avoiding severe vascular events are largely offset by the increased risk of bleeding.
Prof. Freek W. A. Verheugt in an interview at the ESC 2018 on the influence of mental status on the treatment success of older cardiology patients.
Louise Bowman in an interview at the ESC 2018 on the need for a revised version of the guideline recommendations on the supplementation of omega-3 fatty acids.
To date, no pharmacological agent to support weight loss has convincingly demonstrated cardiovascular safety in a rigorous clinical trial, said Erin A. Bohula May in an esanum interview during the ESC 2018.